Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms — RAPNEN  

Neuroendocrine Tumors Clinical Trial

Official title: Safety and Efficacy of Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment of Functional and Non-functional Pancreatic NeuroEndocrine Neoplasms: A Multicenter Prospective Study

Status Completed

Clinical Trial Summary

This study evaluates the possibility and the safety of performing local therapy for Pancreatic neuroendocrine neoplasms (PanNENs) using radiofrequency ablation of the tumor under ultrasonography (EUS) guidance.

Clinical Trial Description

Pancreatic neuroendocrine neoplasms (PanNENs) are rare, but their incidence has significantly increased in the last decades. The mainstay treatment of PanNENs is surgery, which is associated with a significant benefit in term of survival but also with significant short- and long-term adverse events.

Based on the above data, less invasive alternative therapeutic interventions to avoid short- and long-term adverse events of surgery are needed.

In this context radiofrequency ablation has been reported to be effective in the treatment of these tumors in absence of major adverse events. However, the available studies on the matter are limited by small sample size and lack of standardized criteria for patient selection. ;

Related Conditions & MeSH terms

• Carcinoma, Neuroendocrine
• Neoplasms
• Neuroendocrine Carcinoma
• Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
• Neuroendocrine Tumors
• Pancreas Neoplasm
• Pancreatic Neoplasms

• NCT number: NCT03834701
• Study type: Interventional
• Source: Catholic University of the Sacred Heart
• Status: Completed
• Phase: N/A
• Start date: September 1, 2019
• Completion date: February 1, 2024